Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) Short Interest Update

Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) was the recipient of a significant increase in short interest in the month of January. As of January 30th, there was short interest totaling 259,453 shares, an increase of 154.8% from the January 15th total of 101,823 shares. Based on an average trading volume of 82,534 shares, the short-interest ratio is presently 3.1 days. Approximately 3.9% of the company’s shares are short sold. Approximately 3.9% of the company’s shares are short sold. Based on an average trading volume of 82,534 shares, the short-interest ratio is presently 3.1 days.

Institutional Trading of Calidi Biotherapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. DRW Securities LLC bought a new position in Calidi Biotherapeutics in the 4th quarter worth about $173,000. Geode Capital Management LLC lifted its holdings in Calidi Biotherapeutics by 41.7% in the 4th quarter. Geode Capital Management LLC now owns 41,929 shares of the company’s stock valued at $49,000 after acquiring an additional 12,334 shares during the last quarter. Finally, Warberg Asset Management LLC bought a new stake in shares of Calidi Biotherapeutics during the 3rd quarter worth $28,000. 12.53% of the stock is owned by institutional investors and hedge funds.

Calidi Biotherapeutics Price Performance

CLDI stock traded up $0.02 during midday trading on Friday, reaching $0.78. 235,089 shares of the company’s stock traded hands, compared to its average volume of 80,704. The company has a current ratio of 2.12, a quick ratio of 2.12 and a debt-to-equity ratio of 0.11. Calidi Biotherapeutics has a fifty-two week low of $0.72 and a fifty-two week high of $19.20. The business has a 50-day moving average price of $1.13 and a two-hundred day moving average price of $1.89.

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) last announced its earnings results on Thursday, November 13th. The company reported ($2.21) EPS for the quarter. As a group, research analysts anticipate that Calidi Biotherapeutics will post -4.48 earnings per share for the current year.

Calidi Biotherapeutics Company Profile

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors.